Allied Market Research

2024

Endocrinology Drugs Market

Endocrinology Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report by Therapy Area and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Endocrinology is the branch of medicine that deals with endocrine and metabolic disorders.  Three different classes of hormones based on their chemical composition include amines, steroids, and peptides & proteins. The endocrine system is made of hormone-producing glands, such as the pancreas, thyroid, parathyroid, adrenals, testes, ovaries, pituitary, and hypothalamus. These hormones control metabolism, reproduction, growth, and development.

Doctors who are specially trained in treating hormone imbalances and disorders are known as endocrinologists. Most endocrine disorders are chronic and need constant treatment. Some commonly treated endocrine disorders are osteoporosis, diabetes mellitus, thyroid, and hyperparathyroid disorders. Some less common but serious endocrine disorders are Cushing’s syndrome, Addison’s disease, pheochromocytoma, and diseases of sexual development.

COVID-19 Impact analysis

  • Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global endocrinology drugs market.

Top Impacting Factors
Increase in the prevalence of endocrine hormone-related diseases propels the growth of the endocrinology drugs market.
The presence of robust product pipelines in the endocrinology drugs market for the treatment of both types of diabetes mellitus will boost the market growth.
Extensive research and development, initiation of new drug delivery systems, and rise in disposable income propel the growth of the endocrinology drugs market. 
Rapid uptake of novel dosage forms and formulations of present drugs is expected to increase the number of patients for the treatment of endocrine disorders, thus augmenting market growth. 
On the contrary, illegal use of certain drugs by sports professionals poses a danger to society, thereby deterring the growth of the endocrinology drugs market.
Rising number of cases of hypogonadism in men, provoked by diabetes, heart, or renal disorders is anticipated to create lucrative opportunities for market players.
Increasing awareness among people about diabetes, thyroid, and other hormone-related disorders is further expected to drive the market growth during the forecast period.

Surge in usage in endocrinology drugs

  • The global endocrinology drugs market is expected to observe lucrative growth during the forecast period, due to increase in prevalence of endocrine diseases. These diseases include endocrine gland-associated conditions such as diabetes, gigantism, goiter, Cushing’s syndrome, Addison’s disease, polycystic ovary syndrome (PCOS), thyroiditis, osteomalacia, hyperlipidemia, acromegaly, and hypertension.
  • The rising adolescent population is more prone to such diseases due to hormonal imbalances, which drives the growth of the endocrinology drugs market. Unhealthy lifestyle characteristics such as high intake of cholesterol, weight gain, and work stress lead to malfunctioning of the endocrine system.

Key Benefits of the Report

  • This study presents the analytical depiction of the endocrinology drugs market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed endocrinology drugs market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Endocrinology Drugs Report

  • Who are the leading market players active in the endocrinology drugs market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What future projections would help in taking further strategic steps?
  • What is "endocrinology drugs market "?
  • What is "endocrinology drugs” market prediction in the future?
  • Who are the leading global players in the "endocrinology drugs" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "endocrinology drugs" market report?

Endocrinology Drugs Market Report Highlights

Aspects Details
icon_5
By Therapy Area
  • Diabetes Drugs
  • Thyroid Hormone Disorder Drugs
  • HGH
  • Testosterone Replacement Therapy
  • Others
icon_6
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
icon_7
Key Market Players

Novartis International AG,, F. Hoffmann La Roche Ltd.,, Eli Lilly and Company,, Alacer Corporation,, Facet Biotech Corporation,, Novo Nordisk A/S,, Abbott Laboratories,, Sanofi., Pfizer Inc.,

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Endocrinology Drugs Market

Global Opportunity Analysis and Industry Forecast, 2023-2032